Allterum is developing 4A10, a monoclonal antibody targeted against IL-7Rα. IL-7Rα is part of a receptor complex located on T-cell and B-cell leukemia cells. Especially in the context of T-cell leukemia cells, IL-7Rα plays a critical role in driving cancer growth. IL-7Rα is frequently expressed at a higher level, or is more active, in T-cell leukemia cells, and has been posited as playing a key role in ALL oncogenesis and chemotherapy-resistance. Allterum’s 4A10 antibody is the first immunotherapy approach to target IL-7Rα in leukemia. 4A10 uses the patient’s own immune system to target leukemia cells for destruction. 4A10 is currently in development for the treatment of relapsed pediatric leukemia.